Premium
Efficacy of 90 Yttrium‐ibritumomab tiuxetan in relapsed/refractory extranodal marginal‐zone lymphoma
Author(s) -
Vanazzi Anna,
Grana Chiara,
Crosta Cristiano,
Pruneri Giancarlo,
Rizzo Stefania,
Radice Davide,
Pinto Antonello,
Calabrese Liliana,
Paganelli Giovanni,
Martinelli Giovanni
Publication year - 2014
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2078
Subject(s) - ibritumomab tiuxetan , medicine , radioimmunotherapy , refractory (planetary science) , marginal zone , nuclear medicine , lymphoma , gastroenterology , surgery , immunology , antibody , b cell , physics , monoclonal antibody , astrobiology
We evaluated clinical activity of 90 Yttrium‐ibritumomab ( 90 Y‐ibritumomab) tiuxetan in extranodal marginal‐zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal‐zone lymphoma—arisen at any extranodal site—received 90 Y‐ibritumomab tiuxetan at the activity of 0.4 mCi/kg. Median age was 57 years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow‐up of 5.3 years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3 years, 12 of them after >5 years. 90 Y‐ibritumomab tiuxetan seems to be active in patients with extranodal marginal‐zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients. Copyright © 2013 John Wiley & Sons, Ltd.